Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Introduction: An estimated 50% of men with prostate cancer will eventually need androgen deprivation therapy (ADT), but conflicting evidence exists as to whether ADT is associated with dementia or cognitive impairment. Furthermore, the differential risk of first-generation ADT versus next-generation ADT have yet to be explored. Against this backdrop, we examine the association between ADT and...

  • Interesting study looking at neurocognitive impairment associated with hormonal therapies in prostate cancer.